Comparative Pharmacology
Head-to-head clinical analysis: MOLINDONE HYDROCHLORIDE versus NAVANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOLINDONE HYDROCHLORIDE versus NAVANE.
MOLINDONE HYDROCHLORIDE vs NAVANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dopamine D2 receptor antagonist; also blocks serotonin 5-HT2A receptors and alpha-adrenergic receptors.
Thioxanthene neuroleptic; blocks postsynaptic dopamine D1 and D2 receptors in the brain; also exhibits anticholinergic, alpha-adrenergic blocking, and sedative effects.
50-225 mg/day orally in 3-4 divided doses; usual effective dose 50-75 mg/day; maximum 225 mg/day.
Oral: 10-20 mg three times daily; maximum 160 mg/day. IM (acute): 5-10 mg every 4-6 hours; maximum 30 mg/day.
None Documented
None Documented
1.5-2 hours; shorter than typical antipsychotics, requiring multiple daily dosing.
Terminal elimination half-life is approximately 20-24 hours, allowing for once-daily dosing. Steady-state reached in 4-5 days.
Renal: 65-70% as metabolites and unchanged drug; Fecal: 20-25%; Biliary: minor.
Primarily hepatic metabolism; approximately 20-30% excreted renally as metabolites, <1% unchanged. Biliary/fecal excretion accounts for ~50% of metabolites.
Category C
Category C
Antipsychotic
Antipsychotic, Typical